Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$166.97K$166.97Kderived+980.2% vs Q4 2017 Net Income-$978.89K-$978.89KderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$165,621+1,029.7% Operating Incomederived-$723,118N/M Operating Cash Flowderived-$1,042,028N/M Margins · derivedGross margin99.2%+4.3 pt vs Q4 2017
Operating margin-433.1%+6363.0 pt vs Q4 2017
Net margin-586.3%+8714.4 pt vs Q4 2017
ended Dec 31, 2018 · filed Apr 8, 2019 · 98 d after period end